Evaluation of whole-body MRI for cancer early detection in Li-Fraumeni syndrome
Open Access
- 30 June 2025
- journal article
- Published by BMJ in Journal of Medical Genetics
- Vol. 62 (10)
Abstract
Li-Fraumeni syndrome (LFS) is a high-risk hereditary cancer predisposition syndrome affecting 1 in 5000 individuals. Current standard of care in adults includes annual whole-body MRI (WB-MRI) and MRI brain (MRB) surveillance to enable early cancer detection. We performed a retrospective single-centre study of adults withTP53pathogenic germline variants or proven somatic mosaicism undergoing annual WB-MRI surveillance between January 2012 and January 2024, and MRB surveillance between August 2017 and January 2024. 325 WB-MRI scans were performed in 75 individuals. 17 cancers were diagnosed in 16 individuals. Nine out of 17 cancers were WB-MRI detected (7/9 had stage 1/2 disease). Benign incidental findings were identified in 89/325 (27.4%) of WB-MRI scans, prompting 53 additional investigations. As a stand-alone surveillance tool, WB-MRI demonstrated a pan-cohort specificity of 95.5%, negative predictive value of 97.4% and sensitivity of 42.9%. 32 individuals underwent 53 MRB scans detecting one cancer. We report the findings from the longest and largest single-centre experience of WB-MRI surveillance for cancer early detection in adults with LFS, demonstrating a high and acceptable level of cancer exclusion but modest sensitivity with WB-MRI prompting a significant number of additional investigations.Keywords
Funding Information
- Prevent Breast Cancer (GA25-01)
- International Alliance for Cancer Early Detection (ACEDAS-2023/10000)
- NIHR Manchester Biomedical Research Centre (NIHR203308)
- Cancer Research UK (EDDPMA-Nov22/100019)
This publication has 19 references indexed in Scilit:
- Avoidance or adaptation of radiotherapy in patients with cancer with Li-Fraumeni and heritable TP53-related cancer syndromesThe Lancet Oncology, 2021
- Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data SetJAMA Oncology, 2021
- Guidelines for the Li–Fraumeni and heritable TP53-related cancer syndromesEuropean Journal of Human Genetics, 2020
- Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance ImagingJAMA Oncology, 2017
- InheritedTP53Mutations and the Li–Fraumeni SyndromeCold Spring Harbor Perspectives in Medicine, 2017
- Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controlsFamilial Cancer, 2017
- Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational studyThe Lancet Oncology, 2016
- Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational studyThe Lancet Oncology, 2011
- Prediction of pathogenic mutations in patients with early-onset breast cancer by family historyThe Lancet, 2003
- Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other NeoplasmsScience, 1990